Posters Archives

AMP

Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects

2021-03-05T20:49:11-08:00March 5th, 2021|2019 Posters, AMP, Posters|

AMP

Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies

2021-03-05T20:44:34-08:00March 5th, 2021|2019 Posters, AMP, Posters|

AMP

Comparing DNA Extraction Methods for the LymphoTrack^® IVD TRG Assay

2021-03-05T20:38:02-08:00March 5th, 2021|2019 Posters, AMP, Posters|

AMP

A Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus

2021-03-03T23:53:52-08:00March 3rd, 2021|2019 Posters, AMP, Posters|

EHA

TRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies

2021-03-03T23:55:00-08:00March 3rd, 2021|2020 Posters, EHA, Posters|

ASH

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas

2021-03-03T23:40:33-08:00March 3rd, 2021|2020 Posters, ASH, Posters|

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

AMP

Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects

AMP

Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies

AMP

Comparing DNA Extraction Methods for the LymphoTrack^® IVD TRG Assay

AMP

A Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus

EHA

TRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies

ASH

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

AMP Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects

AMP Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies

AMP Comparing DNA Extraction Methods for the LymphoTrack® IVD TRG Assay

AMPA Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus

EHATRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies

ASHEnd of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

AMP

Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects

AMP

Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies

AMP

Comparing DNA Extraction Methods for the LymphoTrack^® IVD TRG Assay

AMP

A Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus

EHA

TRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies

ASH

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas